By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

News Junction

Notification Show More
Font ResizerAa
  • Home
  • World News
    World NewsShow More
    Royal Caribbean Is Temporarily Rerouting Cruises That Depart From 3 Florida Cities—Here’s Why
    Royal Caribbean Is Temporarily Rerouting Cruises That Depart From 3 Florida Cities—Here’s Why
    April 26, 2025
    How much foreign aid is spent domestically rather than overseas?
    How much foreign aid is spent domestically rather than overseas?
    April 26, 2025
    Pakistan and India border closure separates families
    Pakistan and India border closure separates families
    April 26, 2025
    Funeral set to be one of the most historically charged in living memory
    Funeral set to be one of the most historically charged in living memory
    April 25, 2025
    Russian general killed in car bomb attack near Moscow | World News
    Russian general killed in car bomb attack near Moscow | World News
    April 25, 2025
  • Business
    BusinessShow More
    Ukraine blows up bridges to consolidate its positions in Russia
    Ukraine blows up bridges to consolidate its positions in Russia
    August 18, 2024
    Commentary: AI phones from Google and Apple will erode trust in everything
    Commentary: AI phones from Google and Apple will erode trust in everything
    August 18, 2024
    The most famous Indian Dishes – Insights Success
    The most famous Indian Dishes – Insights Success
    August 18, 2024
    Life on the road as a female long rides cyclist
    Life on the road as a female long rides cyclist
    August 18, 2024
    UK inflation rises to 2.2%
    UK inflation rises to 2.2%
    August 18, 2024
  • Cryptocurrency
    CryptocurrencyShow More
    BlackRock, five others account for 88% of all tokenized treasury issuance
    BlackRock, five others account for 88% of all tokenized treasury issuance
    April 26, 2025
    Traders still offloading TRUMP holdings after dinner announcement — Nansen
    Traders still offloading TRUMP holdings after dinner announcement — Nansen
    April 26, 2025
    Ronin Bridge migrates to Chainlink cross-chain interoperability protocol
    Ronin Bridge migrates to Chainlink cross-chain interoperability protocol
    April 26, 2025
    Is Bitcoin set for a short squeeze? Analyst points to Binance data
    Is Bitcoin set for a short squeeze? Analyst points to Binance data
    April 26, 2025
    Crypto Leader Bybit Powers TOKEN2049 Dubai – Attends as Gold Sponsor, Showcasing Real-World Crypto Utility
    Crypto Leader Bybit Powers TOKEN2049 Dubai – Attends as Gold Sponsor, Showcasing Real-World Crypto Utility
    April 25, 2025
  • Technology
    TechnologyShow More
    How to Improve Your Spotify Recommendations
    How to Improve Your Spotify Recommendations
    August 18, 2024
    X says it’s closing operations in Brazil
    X says it’s closing operations in Brazil
    August 18, 2024
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    August 18, 2024
    Scientists Want to See Videos of Your Cat for a New Study
    Scientists Want to See Videos of Your Cat for a New Study
    August 18, 2024
    OpenAI’s new voice mode let me talk with my phone, not to it
    OpenAI’s new voice mode let me talk with my phone, not to it
    August 18, 2024
  • Entertainment
  • Sports News
  • People
  • Trend
Reading: Zuranolone: What to know about the breakthrough postpartum depression treatment just approved by the FDA
Share
Font ResizerAa

News Junction

  • World News
  • Business
  • Technology
  • Cryptocurrency
  • Trend
  • Entertainment
Search
  • Recent Headlines in Entertainment, World News, and Cryptocurrency – NewsJunction
  • World News
  • Business
  • Cryptocurrency
  • Technology
  • Entertainment
  • Sports News
  • People
  • Trend
Have an existing account? Sign In
Follow US
News Junction > Blog > Business > Zuranolone: What to know about the breakthrough postpartum depression treatment just approved by the FDA
Zuranolone: What to know about the breakthrough postpartum depression treatment just approved by the FDA
Business

Zuranolone: What to know about the breakthrough postpartum depression treatment just approved by the FDA

Published August 5, 2023
Share
7 Min Read
SHARE

The U.S. Food and Drug Administration on Friday approved the first pill designed specifically to treat postpartum depression.

Contents
Improvement in just 3 daysNo weight gain or reduction in libido, trials showDrug not yet approved for major depressive disorder

Zuranolone, trade name Zurzuvae—a steroid that works to rapidly repair dysregulated neuronal networks in the brain—is only the second drug approved for the condition, thought to affect one in seven women. The other, Zulresso (brexanolone), was approved by the FDA in 2019. But it’s administered via IV over time and requires a hospital admission, making it inaccessible to many women.

Such a barrier doesn’t exist with the newly approved drug, taken at home once daily for two weeks. For many women, one or two courses of the medication over a year will be enough to send them into remission and keep them there, Dr. Kristina Deligiannidis—director of women’s behavioral health at Zucker Hillside Hospital in Queens, N.Y., and lead clinical trial investigator for the drug—told Fortune on Wednesday, ahead of the FDA’s decision.

“Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in severe cases, thoughts of harming themselves or their child. And because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child’s physical and emotional development,” Dr. Tiffany R. Farchione, director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, said in a late Friday statement.

“Having access to an oral medication will be a beneficial option for many of these women coping with extreme—and sometimes life-threatening—feelings.”

Improvement in just 3 days

In trials, zuranolone showed a “rapid reduction of depressive symptoms starting as early as day three—after two doses of medicine—and showed continued improvement through day 15,” Deligiannidis said, adding that the drug continues to work even after patients stop taking it, for 45 days in all.

The fast-acting, temporary nature of the drug stands in contrast to standard-of-care antidepressants that might otherwise be prescribed. Such medications—typically SSRIs, or selective serotonin reuptake inhibitors, which increase serotonin levels in the brain—usually take four to six weeks to begin to work, and two to three months to fully kick in, according to Deligiannidis.

Women with postpartum depression are busy sustaining a new life, their own life, and perhaps the lives of other children as well. They can’t wait months for relief, she said: “Especially for women with severe postpartum depression, this could be a life-saving option.”

“It’s like Z-Pak for depression,” Dr. Craig Chepke, medical director of Excel Psychiatric Associates in Huntersville, N.C., and occasional consultant for Zuranolone developer Sage Therapeutics, told Fortune on Wednesday.

He referenced azithromycin, a quick-acting five-day course of pills for bacterial infections like bronchitis and pneumonia often prescribed by general practitioners.

“This is exactly how primary care providers would love to treat depression,” he said of the new drug. “It fits with the model they’re used to. I think they’re going to feel more comfortable, that it’s just like treating a UTI or a sinus infection, and think, ‘I can do that.’”

Because Zuranolone works differently than standard depression treatments, and much more quickly, “it offers a lot of hope for people who haven’t done well in the past,” he added.

No weight gain or reduction in libido, trials show

Clinical trials showed that patients on zuranolone didn’t experience weight gain or reduced sex drive—side effects typical of SSRIs that are often “deal killers” for patients.

Side effects of the new drug may include drowsiness, dizziness, diarrhea, fatigue, the common cold, and urinary tract infections, according to a news release issued Friday by the FDA. But side effects “can’t last longer than two weeks, because you only take it for two weeks,” Chepke noted. “It changes the calculus for a lot of people who would otherwise quit medication.”

Because zuranolone is a controlled substance, the U.S. Drug Enforcement Administration now has 90 days to assign a schedule to it. Earlier this week, Chepke predicted it would be designated a Schedule IV drug, or one with a low potential for abuse and dependence like Xanax, Valium, Ativan, and Ambien.

From there, he anticipated it would soon be in the hands of prescribers and patients, where it’s sorely needed.

Depression is still widely thought of as a nuisance condition in which “you get down from time to time, but your pick yourself up by the bootstraps,” he said. “Even in churches, there’s the notion of ‘too blessed to be stressed.’ It’s as if it’s not a big deal. But it is a big deal. And we need better treatment options to help.”

On Wednesday, Deligiannidis was hopeful word of the FDA’s approval would come before the end of the work week, and with it, a wave of press that encourages new mothers to seek the help they deserve—for their sake, and for their sake of their children.

“Depression can increase the risk for poor birth outcomes,” and such negative outcomes can continue after a child is born, she said.

“For mom’s sake, for baby’s sake, for the family’s sake, we want women to discuss their symptoms with a trusted healthcare provider ASAP.”

Drug not yet approved for major depressive disorder

Sage Therapeutics had also applied for approval to use the drug in cases of major depressive disorder. The federal agency on Friday did not issue a ruling on such use.

In 2021, an estimated 8% of American adults—21 million—had at least one major depressive episode, according to the U.S. National Institutes of Health. If approved for major depressive disorder as well, the drug could shift the paradigm on depression from a chronic condition that requires lifelong medication to an acute illness that, for many, necessitates just a short course of drugs during flares, experts told Fortune.

#Zuranolone #breakthrough #postpartum #depression #treatment #approved #FDA

TAGGED:ApprovedbreakthroughdepressionfdaPostpartumtreatmentZuranolone
Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Why Cowboys extended Malik Hooker — and how do they see the safety position? Why Cowboys extended Malik Hooker — and how do they see the safety position?
Next Article Donut-Shaped Frozen Desserts : donut dessert bars Donut-Shaped Frozen Desserts : donut dessert bars

You Might Also Like

Mounjaro: New weight loss drug approved for use in Britain to be available ‘within weeks’ | UK News
Technology

Mounjaro: New weight loss drug approved for use in Britain to be available ‘within weeks’ | UK News

January 26, 2024
Oklo Publishes Second Quarter 2024 Earnings and Business Update By Investing.com
Business

Oklo Publishes Second Quarter 2024 Earnings and Business Update By Investing.com

August 14, 2024
Dominion Energy breaks ground on huge solar farm at D.C.’s Dulles Airport (NYSE:D)
Business

Dominion Energy breaks ground on huge solar farm at D.C.’s Dulles Airport (NYSE:D)

August 23, 2023
NatWest boss steps down with immediate effect over Nigel Farage bank account leak
Business

NatWest boss steps down with immediate effect over Nigel Farage bank account leak

July 26, 2023

About Us

NEWS JUNCTION (NewsJunction.xyz) Your trusted destination for global news. Stay informed with our timely and accurate reporting on diverse topics, including politics, technology, science, entertainment, sports, and more. Count on us for unbiased and reliable updates at your fingertips.

Quick Link

  • About
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Contact

Top Categories

  • World News
  • Business
  • Technology
  • Entertainment
  • Cryptocurrency
  • Sports News
  • Trend
  • People

Subscribe

Subscribe to our newsletter to get our newest articles instantly!

    © 2023 News Junction.
    • Blog
    • Advertise
    • Contact
    Welcome Back!

    Sign in to your account

    Username or Email Address
    Password

    Lost your password?